Drug
Vamorolone clinical trials
Also written VBP15.
Includes 1 study of Vamorolone acetate.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2024 (3)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2020 | 1 |
| 2022 | 2 |
| 2024 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 6
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 0
ReveraGen BioPharma, Inc. (6) · Santhera Pharmaceuticals (4)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses vamorolone is read from its arms, and is right about nine times in ten.
Testing it · 10
- A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD)CompletedPhase 2ReveraGen BioPharma, Inc.NCT05166109Written as Vamorolone
- A Study on Safety and Effectiveness of Long-term Treatment With Vamorolone in Boys With Duchenne Muscular DystrophyActive, not recruitingPhase 4Santhera PharmaceuticalsNCT06713135Written as vamorolone 40 mg/mL oral suspension
- Evaluation of Vamorolone CYP3A4 Induction on Midazolam (a Sensitive CYP 3A4 Substrate) PharmacokineticsCompletedPhase 1Santhera PharmaceuticalsNCT06689527Written as Vamorolone
- A Study to Assess Vamorolone in Boys Ages 2 to <4 Years and 7 to <18 Years With Duchenne Muscular Dystrophy (DMD)CompletedPhase 2Santhera PharmaceuticalsNCT05185622Written as Vamorolone
- Evaluation of Vamorolone Mineralocorticoid Receptor Antagonism in Healthy SubjectsCompletedPhase 1Santhera PharmaceuticalsNCT06649409Written as Vamorolone
- Long-term Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)CompletedPhase 2ReveraGen BioPharma, Inc.NCT03038399Written as Vamorolone 0.25 mg/day/day
- Proof of Concept Trial of Vamorolone in Pediatric Ulcerative ColitisWithdrawnPhase 1/2ReveraGen BioPharma, Inc.NCT04348890Written as Vamorolone 4% suspension for oral dosing
- An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)CompletedPhase 2ReveraGen BioPharma, Inc.NCT02760277Written as Vamorolone 0.25 mg/day/day
- A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)CompletedPhase 2ReveraGen BioPharma, Inc.NCT02760264Written as Vamorolone 0.25 mg/kg/day
- A Phase 1 Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VBP15 in Healthy Adult SubjectsCompletedPhase 1ReveraGen BioPharma, Inc.NCT02415439Written as VBP15
Given in every arm · 1 — vamorolone is usual care beside what is tested
Codes
What other systems call vamorolone · ClinicalTrials.gg INT006390
- MeSH (NLM) C584811vamoroloneConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 8XP29XMB43VAMOROLONEConfirmed FDA, NLM, Wikidata
- Wikidata Q27089127vamoroloneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152825VamoroloneOne source FDA
- DrugBank DB15114One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C584811 | vamorolone | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 8XP29XMB43 | VAMOROLONE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27089127 | vamorolone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152825 | Vamorolone | One source FDA |
| DrugBank | DB15114 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.